A Phase III Study of M610101 in Patients with Atopic Dermatitis

A Phase III, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of M610101 in Patients with Atopic Dermatitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031260244

Enrollment

150

Registered

2026-06-22

Start date

2026-06-22

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Apply 2 times a day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with atopic dermatitis aged 2 years to 12 years (2)Patients with an IGA score of 2 or 3 for atopic dermatitis (3)Patients with 3% to 20% BSA involvement of atopic dermatitis

Exclusion criteria

Exclusion criteria: (1)Patients complicated with diseases considered inappropriate for participation in clinical trials such as serious cardiac / hepatic / renal / pulmonary / hematologic disease (2)Patients with skin diseases other than atopic dermatitis that affect the evaluation of atopic dermatitis or the safety of the subject

Design outcomes

Primary

Measure	Time frame
Proportion of participants achieving an IGA score of 0 or 1 with at least a 2-point improvement from baseline at week 8	—

Contacts

Public ContactClinical Trials Information -

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026